Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)
Amylyx Pharmaceuticals' (AMLX) quarterly Restructuring Costs came in at $22.9 million in Q2 2024.
Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024) Analysis & Trends
Amylyx Pharmaceuticals' Restructuring Costs history runs 1 years deep, the most recent figure standing at $22.9 million for Q2 2024.
- On a quarterly basis, Restructuring Costs changed N/A year-over-year to $22.9 million in Q2 2024; TTM through Jun 2025 was $22.9 million, a N/A change from a year earlier, with the FY2024 full-year figure at $22.9 million, changed N/A from the prior year.
- Restructuring Costs held at $22.9 million in Q2 2024 per AMLX's latest filing.
- Across five years, Restructuring Costs topped out at $22.9 million in Q2 2024 and bottomed at $22.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn |
| 3 | Zoetis | 32.62 Bn | 30.68 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Amylyx Pharmaceuticals | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 22.85 Mn |